MedTrace Logo

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

NCT02487316 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2016-12-30

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of crizotinib combined with CHOP chemotherapy for patients with ALK(+) Systemic Anaplastic Large Cell Lymphoma.

Conditions

  • Systemic Anaplastic Large-Cell Lymphoma

Interventions

DRUG

crizotinib

crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Peking University People's Hospital

    collaborator OTHER

  • Peking University Third Hospital

    collaborator OTHER

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Beijing Hospital

    collaborator OTHER_GOV

  • Chinese PLA General Hospital

    collaborator OTHER

  • First Hospitals affiliated to the China PLA General Hospital

    collaborator OTHER_GOV

  • Air Force General Hospital of the PLA

    collaborator OTHER_GOV

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    collaborator OTHER

  • Anhui Provincial Hospital

    collaborator OTHER_GOV

  • Zhejiang University

    collaborator OTHER

  • Jun Zhu

    lead OTHER

Principal Investigators

  • Jun Zhu, MD · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-11-30
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02487316 on ClinicalTrials.gov